All companies know what they do and how they do it.
But only a few know “why” they do it.
At Dipharma SA we started from here: our “why”. Why not exploring new avenues in the pharmaceutical business to benefit to all those involved: patients, doctors, partners, employees? Why not rendering it simpler to make a difference in their lives?
Dipharma S.A. is part of a third-generation group of family-owned companies that have grown to a global presence.
With a portfolio of generic orphan products for the treatment of Phenylketonuria, Gaucher Disease, Hereditary Tyrosinemia Type 1, Urea Cycle Disorders and others, Dipharma S.A. provides improved solutions for patients affected by inborn metabolic diseases at an affordable cost and with a global reach.
Drug development
Drug commercialization
Metabolism
CH
EU Top 5
Rest of Europe
USA and Canada
Japan (Partial)
LATAM (Partial)
MENA (Partial)
BRICS (Partial)
ASEAN (Partial)
Australia
Other market
Generic
Oral (solid)
Swissmedic
GMP
